Metformin, a drug approved by the U.S. Food and Drug Administration (FDA) for use in patients with diabetes, has been shown to improve fatty livers in animals and in a small number of human beings.

The purpose of this study is to find out if Metformin is safe and useful in the treatment of non-alcoholic fatty liver disease (NAFLD).

Eligibility Criteria

To participate in this study, you must:

• Be between the ages of 18 and 75
• Have a confirmed diagnosis of NAFLD
• Not have any form of chronic liver disease other than NAFLD

Study Requirements

Your participation in this study will last about two years. You will be randomly assigned to receive either Metformin or a placebo for one year. After your year of dosing, there will be a follow-up period that lasts for another year.

For more information, contact Christopher Kigongo at 919-668-6579.